Bob Ryder
Co-opted member of ABCD (Diabetes Care) Committee; Website Co-ordinator & Clinical Lead, Nationwide Audits of New Diabetes Therapies
Bob is a consultant at City Hospital, Birmingham.
Bob's major interests lie in research and audit. A current major interest is community diabetes and a project which won the QIC best primary and/or community initiative in 2014. Over the years special interests have included photographic screening for diabetic retinopathy – He undertook much of the groundwork behind the current national eye screening programme; lactic acidosis; symptoms of ovulation; diabetic hypoglycaemia unawareness; diabetic autonomic neuropathy; diabetic impotence; clinical use of IT, most recently to support Think Glucose; treating to target; relative risks and benefits of pioglitazone (especially its insufficiently recognised cardio-protective properties).
Bob manages the ABCD website and is lead for the ABCD nationwide audits of new therapies, most recently establishing for this purpose an ABCD presence on N3, the national broadband network of the NHS. Current and imminent audits include exenatide qw, dapagliflozin, canagliflozin, empagliflozin, IDegLira and insulin degludec. He is chief investigator for ABCD's multi-centre endobarrier study (REVISE-Diabesity) and the ABCD study of Endobarrier in Diabetes with Obstructive Sleep apnoea (End-OSA). Beyond diabetes he is best known for being principal author of the best-selling "An Aid to the MRCP Short Cases", the fourth edition of which is “An Aid to the MRCP PACES” consisting of volume 1, volume 2 and volume 3.
Contact Dr Ryder HERE
